Tweets
EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 10 months ago
Points to consider in pregnancy &lactation in Pts w #rheumatic #diseases
#biologics don’t increase rate of serious infections in
Mom
Baby
Compared to other matched pregnant and post partum women
reassuring!
#EULAR2024
@RheumNow @eular_org
Janet Pope @Janetbirdope ( View Tweet )
1 year 10 months ago
What to use in men prior to planned conception of partner in
#rheumatic #diseases
#EULAR2024 @RheumNow @ACRheum @eular_org https://t.co/jMecV8jqUe
Janet Pope @Janetbirdope ( View Tweet )
1 year 10 months ago
MINIMAL SPINAL RADIOGRAPHIC PROGRESSION in RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY - 90% nonprogressers on Bime including how many would never have progressed ? @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 10 months ago
Points to consider in pregnancy in
#rheumatic diseases
3 points
✅TNFi all OK 👍
? Only if you can’t control disease use other #bDMARDs
Baby #vaccinations if exposed to #biologics while present
#rotovirus ok
other live vaccines >6 mos
#EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh
Links:
Janet Pope @Janetbirdope ( View Tweet )
1 year 10 months ago
POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA
Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i
@SteZhao @RheumNow #EULAR2024
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 10 months ago
1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s @RheumNow #EULAR2024 https://t.co/SM5CA7KUvd
Peter Nash @drpnash ( View Tweet )
1 year 10 months ago
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 10 months ago
New reccs for knee/hip #OA w/2 overarching principles
1. Biopsychosocial approach
2.Individualized Rx w/shared decision making (includes education, diet/exercise, healthy weight, appropriate assistive device/footware, modify work factors, pain coping skills)
#EULAR24
@rheumnow https://t.co/0LVLBMGO7L
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 10 months ago
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 year 10 months ago
#EULAR2024 LBA0010 Promising Tx with diff mode of action in antibody+ #Sjogren. Phase 2 RCT Nipocalimab, anti-neonatal Fc receptor (FcRn)Ab that reduces IgG, met primary endpoint (clinESSDAI). Low SIE but doubled in lowest dose vs PBO (unrelated to IgG). On to Phase3 @RheumNow https://t.co/NlCc2l4zFL
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 10 months ago
#EULAR2024 LBA0007 More evidence on deep Bcell depletion in #lupus. Open label trial of Daratumumab, anti-CD38 plasma cell Ab showed rapid reduction in biomarker endpoint, dsDNA, as well as SRI-4 & CLASI-A at Wk12. No SAE but longer F/U needed since IgG reduced by 6g/L @RheumNow https://t.co/IIFPYV9oIr
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 10 months ago
